Insider transactions

EDGAR

Prevail Therapeutics Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

This issuer has insider filings in the store, but no transaction in this window or code group.

Latest reported holdings

What each reporting owner last said they hold, as of the date shown. A transaction not yet filed is not in it.

No holding was reported in this window.

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read from their tags. Earlier schedules are free text: they are read only when every cover page states a share count and a percent, and the rest are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
ELI LILLY AND COMPANY Common Stock, par value $0.0001 per share53.318,858,511— Filed 2020-12-22SC 13DRead from the cover page textOpen filing 0001193125-20-323947 Dispute this row
TYTO ACQUISITION CORPORATION Common Stock, par value $0.0001 per share53.318,858,511— Filed 2020-12-22SC 13DRead from the cover page textOpen filing 0001193125-20-323947 Dispute this row
RA Capital Management, L.P. Common Stock, par value $0.0001 per share9.93,363,605— Filed 2020-02-14SC 13GRead from the cover page textOpen filing 0001104659-20-021902 Dispute this row
Peter Kolchinsky Common Stock, par value $0.0001 per share9.93,363,605— Filed 2020-02-14SC 13GRead from the cover page textOpen filing 0001104659-20-021902 Dispute this row
Rajeev Shah Common Stock, par value $0.0001 per share9.93,363,605— Filed 2020-02-14SC 13GRead from the cover page textOpen filing 0001104659-20-021902 Dispute this row
EcoR1 Capital, LLC Common Stock, par value $0.0001 per share6.62,248,306— Filed 2020-02-14SC 13G/AAmendment 1Read from the cover page textOpen filing 0000935836-20-000149 Dispute this row
Oleg Nodelman Common Stock, par value $0.0001 per share6.62,248,306— Filed 2020-02-14SC 13G/AAmendment 1Read from the cover page textOpen filing 0000935836-20-000149 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock, par value $0.0001 per share5.31,818,772— Filed 2020-02-14SC 13G/AAmendment 1Read from the cover page textOpen filing 0000935836-20-000149 Dispute this row
REGENXBIO Inc. Common Stock, par value $0.0001 per share5.952,030,000— Filed 2020-02-13SC 13GRead from the cover page textOpen filing 0001193125-20-035624 Dispute this row
EcoR1 Capital, LLC Common Stock, par value $0.0001 per share7.02,392,556— Filed 2019-06-28SC 13GRead from the cover page textOpen filing 0000935836-19-000360 Dispute this row
Oleg Nodelman Common Stock, par value $0.0001 per share7.02,392,556— Filed 2019-06-28SC 13GRead from the cover page textOpen filing 0000935836-19-000360 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock, par value $0.0001 per share5.71,939,606— Filed 2019-06-28SC 13GRead from the cover page textOpen filing 0000935836-19-000360 Dispute this row
OrbiMed Advisors LLC COMMON STOCK40.713,822,463— Filed 2019-06-27SC 13DRead from the cover page textOpen filing 0000947871-19-000475 Dispute this row
OrbiMed Capital GP VI LLC COMMON STOCK40.713,822,463— Filed 2019-06-27SC 13DRead from the cover page textOpen filing 0000947871-19-000475 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

3,104,499 filings read, dated 1980-01-02 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015258,595
2016246,472
2017244,814
2018245,575
2019238,619
2020249,093
2021274,850
2022257,922
2023253,676
2024261,106
2025235,525
2026263,830

Filings made before the SEC required XML are listed, not extracted.

Back to Prevail Therapeutics Inc.